New guidelines: What to do about an unexpected positive tuberculin skin test

Cleveland Clinic Journal of Medicine

Volumn 70, Issue 1, 2003, Pages 49-55

  Curley, Catherine ^a  

^a METROHEALTH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BARBITURIC ACID DERIVATIVE; BCG VACCINE; BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHLORAMPHENICOL; CYCLOSPORIN; CYTOCHROME P450; DIGOXIN; ESTROGEN; ISONIAZID; KETOCONAZOLE; METHADONE; MEXILETINE; ORAL CONTRACEPTIVE AGENT; PYRAZINAMIDE; QUINIDINE; RIFAMPICIN; SULFONYLUREA; THEOPHYLLINE; TOCAINIDE; TUBERCULIN; VERAPAMIL; WARFARIN; ZIDOVUDINE;

CLINICAL FEATURE; COUGHING; DIAGNOSTIC ACCURACY; DIRECTLY OBSERVED THERAPY; DRUG BLOOD LEVEL; DRUG WITHDRAWAL; ENZYME INDUCTION; FEVER; HEMOPTYSIS; HEPATITIS; HIGH RISK PATIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MASS SCREENING; MEDICAL DECISION MAKING; MEDICAL SOCIETY; MYCOBACTERIUM; MYCOBACTERIUM TUBERCULOSIS; NIGHT SWEAT; PRACTICE GUIDELINE; PREGNANCY; PREVALENCE; REVIEW; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SKIN INDURATION; SKIN TEST; THORAX RADIOGRAPHY; TUBERCULIN TEST; TUBERCULOSIS; UNITED STATES; WEIGHT REDUCTION;

EID: 0037241812     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.70.1.49     Document Type: Review

References (9)

1. The American Thoracic Society and the Centers for Disease Control and Prevention. Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med 2000; 161:S221-S247.
2. Huebner RE, Schein MF, Bass JB Jr. The tuberculin skin test. Clin Infect Dis 1993; 17:968-975.
3. Reichman LB. Tuberculin skin testing. The state of the art. Chest 1979; 76:764-770.
4. Mazurek GH, LoBue PA, Daley CL, et al. Comparison of a whole-blood interferon gamma assay with tuberculin skin testing for detecting latent Mycobacterium tuberculosis infection. JAMA 2001; 286:1740-1747.
5. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha neutralizing agent. N Engl J Med 2001; 345:1098-1104.
6. International Union Against Tuberculosis Committee on Prophylaxis. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: 5 years of follow-up in the IUAT trial. Bull WHO 1982; 60:555-564.
7. Garibaldi RA, Drusin RE, Ferebee SH, Gregg MB. Isoniazid-associated hepatitis. Report of an outbreak. Am Rev Respir Dis 1972; 106:357-365.
8. Kopanoff DE, Snider DE Jr, Caras GJ. Isoniazid-related hepatitis. A US Public Health Service cooperative surveillance study. Am Rev Respir Dis 1978; 117:991-1001.
9. Centers for Disease Control and Prevention. Update: fatal and severe liver injuries associated with rifampin and pyrazinamide for latent tuberculosis infection, and revisions in American Thoracic Society/CDC recommendations-United States, 2001. MMWR 2001; 50:733-735.